{Reference Type}: Journal Article
{Title}: The Combined Use of Inflammation Markers, Modified Glasgow Prognostic Score, and Sarculator Nomogram in Extremity Soft Tissue Sarcoma: A Multicenter Observational Study.
{Author}: Nakamura T;Takenaka S;Outani H;Hagi T;Tamiya H;Imura Y;Asanuma K;Sudo A;
{Journal}: Cancers (Basel)
{Volume}: 16
{Issue}: 5
{Year}: 2024 Mar 6
{Factor}: 6.575
{DOI}: 10.3390/cancers16051077
{Abstract}: <B>BACKGROUND: </B>Sarculator is a validated nomogram designed to predict overall survival (OS) in extremity soft tissue sarcoma (STS). Inflammation plays a critical role in cancer development and progression. There were no reports which investigated the relationship between Sarculator and inflammation.<BR><B>METHODS: </B>A total of 217 patients with extremity STS were included. The Sarculator-predicted 10-year probability of OS (pr-OS) was stratified into two subgroups: lower risk (10-year pr-OS ≥ 60%) and higher risk (10-year pr-OS < 60%). The modified Glasgow prognostic score (mGPS) varied from 0 to 2.<BR><B>RESULTS: </B>Out of the 217 patients, 67 were classified as higher risk, while 150 were lower risk. A total of 181 patients had an mGPS of 0, and 36 had a score of 1 or 2. The 5-year OS was 83.3%. When patients were divided into two groups according to the 10-year pr-OS, those with a higher risk had poorer OS than those with a lower risk. Among the patients with a higher risk, those with an mGPS of 1 or 2 had poorer OS compared to those with a score of 0.<BR><B>CONCLUSIONS: </B>The mGPS could potentially play an important role in identifying patients who are at high risk of death and metastasis in the higher-risk group on the Sarculator.